Nutrition & Lifestyle
    Retatrutide

    What to Eat on Retatrutide

    What to eat on retatrutide becomes a critical question when appetite is dramatically suppressed by triple-agonist therapy. With retatrutide producing 24% average weight loss in Phase 2 trials (Jastreboff et al., NEJM 2023), the reduced appetite means every meal matters more -- you need to maximize nutritional value from smaller amounts of food to preserve muscle, maintain energy, and support overall health during rapid weight loss.

    Published: April 3, 202613 min read

    One of the most transformative -- and challenging -- aspects of GLP-1 medications is the dramatic reduction in appetite. Patients who once thought about food constantly suddenly find themselves indifferent to meals. While this appetite suppression drives weight loss, it also creates a nutritional challenge: how do you get enough protein, vitamins, and minerals from significantly less food? The answer lies in strategic, protein-first eating that prioritizes nutrient density over volume.

    Nutritional Guidance Notice

    Retatrutide is not FDA-approved for any indication. This nutritional guidance applies to GLP-1 medications generally. Work with a registered dietitian for personalized nutrition planning, especially during significant weight loss. Compounded semaglutide ($99/mo) and tirzepatide ($125/mo) are available now.

    Rule #1: Protein First, Always

    Protein is the most critical macronutrient during GLP-1-mediated weight loss. It preserves lean muscle mass during caloric deficit, provides essential amino acids the body cannot produce, supports immune function and tissue repair, and promotes satiety (complementing the medication's appetite effects). Aim for 1.2-1.6 grams per kilogram of body weight daily. At every meal and snack, eat protein first before other foods.

    Best Protein Sources

    • Lean poultry: Chicken breast, turkey -- high protein, well-tolerated, versatile
    • Fish and seafood: Salmon, shrimp, cod -- omega-3 benefits plus protein
    • Eggs: Complete protein, easy to prepare in small portions
    • Greek yogurt: 15-20g protein per serving, easy on the stomach
    • Cottage cheese: High casein protein, good for sustained amino acid release
    • Lean beef/pork: Iron-rich, satisfying in small portions
    • Protein shakes: Whey or plant-based -- useful when solid food is unappealing

    Foods That Work Well on GLP-1 Medications

    • Soft-textured proteins: Fish, eggs, yogurt -- easier on the stomach with delayed gastric emptying
    • Non-starchy vegetables: Broccoli, spinach, peppers, zucchini -- nutrient-dense, low calorie
    • Complex carbohydrates in moderation: Sweet potatoes, quinoa, brown rice -- sustained energy without blood sugar spikes
    • Healthy fats in small amounts: Avocado, nuts, olive oil -- calorie-dense, so use moderately
    • Fruits: Berries, apples, citrus -- vitamins and fiber, natural sweetness

    Foods to Limit or Avoid

    • Fried and greasy foods: Worsen nausea and GI symptoms significantly
    • Large portions: Delayed gastric emptying makes large meals uncomfortable
    • Sugary beverages: Waste caloric "budget" on nutrition-free calories
    • Highly processed foods: Low nutritional value per calorie
    • Very spicy foods: May exacerbate GI side effects
    • Carbonated drinks: Can worsen bloating

    Meal Timing and Frequency

    With reduced appetite, three large meals may not work. Many patients on GLP-1 medications do better with 4-6 small meals or snacks throughout the day. This approach ensures more consistent protein intake, reduces GI discomfort from large meals, maintains energy levels, and makes it easier to meet nutritional targets.

    Don't Forget Hydration

    Reduced appetite often means reduced thirst. Adequate hydration is essential, especially given the GI side effects of GLP-1 medications that can cause fluid loss. Aim for at least 64 ounces (8 cups) of water daily, more if experiencing diarrhea or vomiting.

    Consider Supplementation

    With reduced food intake, meeting all micronutrient needs through diet alone can be challenging. A high-quality multivitamin, plus additional vitamin D, calcium, and potentially B12 supplementation, may be recommended. Read our supplements guide for detailed recommendations.

    Medical Disclaimer

    This article is for informational purposes only and does not constitute medical or nutritional advice. Retatrutide is not FDA-approved for any indication. Consult a registered dietitian for personalized nutritional guidance during weight loss medication use. Individual nutritional needs vary based on health status, activity level, and medical conditions.

    Start Your Weight Loss Journey With Expert Support

    Compounded semaglutide from $99/mo. Compounded tirzepatide from $125/mo. Physician-supervised care.

    View Treatment Options

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: January 8, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook
    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    Robyn Lynn CurtisFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Step-by-step retatrutide injection: 6-day half-life, once-weekly dosing, site rotation, and how to time shots for fewer side effects and better weight loss results.

    What to expect in your first month on retatrutide: realistic weight loss expectations, side effects, appetite changes, and tips for maximizing early results during the dose titration phase.

    Should you exercise on retatrutide injection day? Practical guidelines for timing workouts around your weekly injection, managing side effects, and maintaining exercise consistency.

    Guide to semaglutide 0.5mg dose increase. Learn what to expect at the first titration step, typical side effects, weight loss results, and when to advance to 1.0mg.

    Start your GLP-1 journey — from $99/mo

    Get Started